誉衡药业：2025年全年净利润同比预增50.37%—80.44%

Core Viewpoint - The company expects a significant increase in net profit for 2025, with projections indicating a rise of 50.37% to 80.44% compared to the previous year, driven by strong sales growth in key products and improved internal management efficiency [1] Financial Projections - The company forecasts a net profit attributable to shareholders of 350 million to 420 million yuan for 2025, representing a year-on-year increase of 50.37% to 80.44% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 185 million and 220 million yuan, reflecting a year-on-year growth of 0.92% to 20.02% [1] Key Growth Drivers - Sales of core products such as injectable multivitamins, potassium chloride sustained-release tablets, and other medications have shown significant and stable growth [1] - Additional contributions to revenue are expected from products like sitagliptin and metformin sustained-release tablets, flurbiprofen ester injection, and injectable papaverine hydrochloride [1] Cost Management - The company has made notable progress in internal management, resulting in a decrease in both sales and administrative expenses compared to the same period last year [1] Non-Recurring Gains - In December 2025, the company will receive the final payment and interest of 132 million yuan from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd., which will be included in the investment income for 2025 as a non-recurring gain [1]